NEXMED RELEASES RESULTS OF PHASE I FUNGUS STUDY

NexMed has reported that an early study showed its topical nail fungus treatment left substantially less drug in the bloodstream than the leading oral medicine, potentially making it a safer therapy.

The company's experimental NM100060 treatment uses a proprietary technology to boost the skin's drug absorption. It contains less than 1 percent of the oral dose of terbinafine, the active ingredient in Novartis AG's Lamisil tablet. The NexMed drug showed peak blood plasma levels about 2,500 times less than those of a single Lamisil tablet, and were comparable with the blood levels of an athlete's foot cream using the same active ingredient.